Overview
- Gender
-
male
- Investor Type
-
Investment Partner,Angel
- Investor Stage
-
Seed
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including nineteen which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Unity Biotechnology (UBX); Sienna Biopharmaceuticals (SNNA); Vir Biotechnology, Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL, Ikaria; Kythera Biopharmaceuticals (KYTH), Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics, KSQ Therapeutics, Beam Therapeutics, NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); Editas (EDIT), IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Fate Therapeutics (FATE); WuxiNextCODE; and Everyday Learning Corporation.
Mr. Nelsen is a director of Vir Bio, GRAIL, Sienna Biopharmaceuticals, Beam Therapeutics, Unity Biotechnology, Denali Therapeutics, Arivale, Syros Pharmaceuticals, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.
Personal Investments
Robert Nelsen has made 3 investments. Their most recent investment was on
Jun 21, 2019, when Gali Health raised $2M.
Jobs
Robert Nelsen has 6 current jobs including
Board Observer at Synchron
,
Board Member at Resilience
and
Co-Founder & Managing Director at ARCH Venture Partners
.